Jonathan E. Kolitz
North Shore University Hospital
Hofstra University School of Medicine
Lake Success
NY 11042
USA
Name/email consistency: high
- P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Kolitz, J.E., George, S.L., Marcucci, G., Vij, R., Powell, B.L., Allen, S.L., DeAngelo, D.J., Shea, T.C., Stock, W., Baer, M.R., Hars, V., Maharry, K., Hoke, E., Vardiman, J.W., Bloomfield, C.D., Larson, R.A. Blood (2010)
- Very late relapse of acute myeloid leukemia. Kolitz, J.E. Leuk. Lymphoma (2007)
- Current therapeutic strategies for acute myeloid leukaemia. Kolitz, J.E. Br. J. Haematol. (2006)
- Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Kolitz, J.E., George, S.L., Dodge, R.K., Hurd, D.D., Powell, B.L., Allen, S.L., Velez-Garcia, E., Moore, J.O., Shea, T.C., Hoke, E., Caligiuri, M.A., Vardiman, J.W., Bloomfield, C.D., Larson, R.A. J. Clin. Oncol. (2004)









